Theravance Biopharma Inc
NASDAQ:TBPH

Watchlist Manager
Theravance Biopharma Inc Logo
Theravance Biopharma Inc
NASDAQ:TBPH
Watchlist
Price: 9.85 USD 0.61% Market Closed
Market Cap: 484.3m USD
Have any thoughts about
Theravance Biopharma Inc?
Write Note

Theravance Biopharma Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Theravance Biopharma Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Theravance Biopharma Inc
NASDAQ:TBPH
Income from Continuing Operations
-$49.4m
CAGR 3-Years
41%
CAGR 5-Years
26%
CAGR 10-Years
14%
No Stocks Found

Theravance Biopharma Inc
Glance View

Market Cap
484.4m USD
Industry
Pharmaceuticals

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. The company is headquartered in George Town, Grand Cayman and currently employs 158 full-time employees. The company went IPO on 2014-05-16. The firm develops transformational medicines to improve the lives of patients suffering from serious illnesses. The firm's research is focused in the areas of inflammation and immunology. The company applies organ-selective knowledge to biologically compelling targets to discover and develop medicines, which are designed to treat underserved localized diseases and to limit systemic exposure. The firm is developing lung-selective medicines to treat respiratory disease, including YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its revefenacin is a long-acting muscarinic antagonist (LAMA). Its programs also include Nezulcitinib, Ampreloxetine (TD-9855), Izencitinib, TD-5202 and TD-8236.

TBPH Intrinsic Value
7.15 USD
Overvaluation 27%
Intrinsic Value
Price

See Also

What is Theravance Biopharma Inc's Income from Continuing Operations?
Income from Continuing Operations
-49.4m USD

Based on the financial report for Sep 30, 2024, Theravance Biopharma Inc's Income from Continuing Operations amounts to -49.4m USD.

What is Theravance Biopharma Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
14%

Over the last year, the Income from Continuing Operations growth was 19%. The average annual Income from Continuing Operations growth rates for Theravance Biopharma Inc have been 41% over the past three years , 26% over the past five years , and 14% over the past ten years .

Back to Top